Drug Profile
Mesalazine controlled-release - Holy Stone Healthcare
Alternative Names: IBD-98; IBD-98-M; Mesalamine-sodium hyalyronicLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Medical and Pharmaceutical Industry Technology and Development Center
- Developer Holy Stone Healthcare
- Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ulcerative colitis
- No development reported Inflammatory bowel diseases
Most Recent Events
- 29 Sep 2021 Mesalazine controlled-release is still in phase II trials for Ulcerative colitis in Italy (Holy Stone Healthcare pipeline, September 2021)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease(In volunteers) in Canada (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Taiwan (PO, Controlled release)